Note 20 - SUBSEQUENT EVENTS
|
12 Months Ended |
---|---|
Dec. 31, 2013
|
|
Notes to Financial Statements | |
Note 20 - SUBSEQUENT EVENTS |
The Company has evaluated subsequent events from the balance sheet date through April 11, 2014, the date the financial statements were available to be issued, and has determined that there are no other events to disclose other than the following:
On January 1, 2014, the Company issued 100,000 shares of its common stock for services rendered.
Effective January 7, 2014, the board of directors and shareholders adopted an amendment to its Articles of Incorporation changing the Companys name to BioCorRx Inc.
On February 4, 2014, the Company entered into a binding letter of intent with Fresh Start NoCal, LLC to grant the right to use and distribute certain therapeutic programs for the territory of Washington D.C., Maryland, Virginia, West Virginia and North Carolina.
On March 10, 2014, the Company entered into advisory board agreements with three members of the advisory board: Mark Sorrentino, MD, Gil Price, MD and Richard Haatvedt. The Company will grant each advisory board member 50,000 stock options to purchase 50,000 shares of the Companys common stock at an exercise price of $0.20 per share.
On March 11, 2014, the Company entered into a binding letter of intent with Fresh Start Private Midwest, LLC to grant the right to use and distribute certain therapeutic programs for the territory of Oklahoma, Missouri and Minnesota. |